Business Wire

IDEMIA

Share
IDEMIA Provides Seamless Biometric Access Control to Digital Garage’s New Headquarters in Japan

IDEMIA, the global leader in Augmented Identity, today announced the first deployment of MorphoWave ™ Compact in Japan to provide high security and convenience for businesses and the public.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200426005034/en/

The contactless fingerprint technology was installed in the new headquarters of Digital Garage, located in the famous Shibuya district in Tokyo. They are the first to experience such a fast, frictionless and seamless biometric access control in Japan, through this deployment conducted in collaboration with IDEMIA’s official value added partner JAPAN AEROSPACE CORPORATION (JAC). JAC also conducted the network configuration using MorphoWave ™ Compact to integrate with Digital Garage’s system.

The Shibuya headquarters’ 450 employees enjoy all the benefits of MorphoWave ™ Compact for office and floor access control. They can authenticate their biometrics by a touchless “wave” gesture of the hand within the MorphoWave ™ Compact reader, which ensures efficiency, convenience, speed and security. This is also a more hygienic verification method since the users’ fingers are not in contact with the biometric sensor, whether accessing the building and floor or being enrolled.

MorphoWave ™ Compact is a biometric reader equipped with 3D fingerprint technology powered by Artificial Intelligence (AI) that can scan four fingers in less than one second. The algorithms in the biometric system ensure high matching accuracy and it enables up to 100,000 users being identified by one device. In a broader view, MorphoWave ™ Compact eliminates the need for cards, remembering PINs, tailgating and importantly, the concern of multiple people touching a surface.

Nezu Nobuyoshi, Managing Director and Vice President of Sales in IDEMIA Japan said: “With the increasing number of access points in buildings and offices, having touchless 3D fingerprint authentication technology is increasingly important to achieve convenience and maximum security. As a leader in biometrics, we want to provide entities with an advanced biometric technology that is convenient to use and allows users to identify themselves without complications.”

A spokesperson from Digital Garage said: “We are proud to be the first in Japan to implement this touchless 3D fingerprint technology for biometric access control, which ensures accurate identification of our employees and visitors. IDEMIA’s technology is the ideal fit for us, thanks to its versatile and easy deployment, accuracy and reliability in fingerprint matching.”

-END-

About IDEMIA

IDEMIA, the global leader in Augmented Identity, provides a trusted environment enabling citizens and consumers alike to perform their daily critical activities (such as pay, connect and travel), in the physical as well as digital space.

Securing our identity has become mission critical in the world we live in today. By standing for Augmented Identity, an identity that ensures privacy and trust and guarantees secure, authenticated and verifiable transactions, we reinvent the way we think, produce, use and protect one of our greatest assets – our identity – whether for individuals or for objects, whenever and wherever security matters. We provide Augmented Identity for international clients from Financial, Telecom, Identity, Public Security and IoT sectors. With 13,000 employees around the world, IDEMIA serves clients in 180 countries.

For further information, go to www.idemia.com / And follow @IdemiaGroup on Twitter

About Digital Garage

Digital Garage is engaged in two recurring businesses: the fintech business, which provides a package of various payment methods to e-commerce operators and face-to-face retailers, and the marketing business, which provides integrated solutions in the digital and real fields. In addition, it is developing investment and development businesses for promising companies around the world. In addition, in collaboration with our core partners, they operate DG Lab, an open innovation R&D organization. As a company that creates new "contexts" in the Internet age, they will connect various businesses and create innovative services.

About JAC

JAPAN AEROSPACE CORPORATION (JAC) has a history of more than 60 years and a core aerospace company of ITOCHU Group, providing unique and specialized services based on the concept of "only one" and "niche top". JAC offers value added "engineering and technical” services and propose business solutions, mainly relating to national security and social infrastructure along with improvement of safety, comfortability and affordability to the Japanese market.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Lone Star Announces Sale of SPX FLOW to ITT Inc.5.12.2025 13:30:00 CET | Press release

Lone Star Funds (“Lone Star”) today announced the signing by an affiliate of Lone Star Fund XI, LP of a definitive agreement to sell SPX FLOW, Inc. (“SPX FLOW”), a leading provider of highly engineered equipment and process technologies for attractive end markets including industrial, health and nutrition, to ITT Inc. (NYSE: ITT) for $4.775 billion in cash and shares of common stock. Based in Charlotte, N.C., SPX FLOW focuses on process technologies delivering mixing, blending, fluid handling, separation, thermal heat transfer and other solutions integral to industrial, health and nutrition markets. The company has operations in more than 25 countries and sales in more than 140 countries. In partnership with Lone Star, SPX FLOW has focused on improving its sales execution and operating platform, while ensuring high quality and innovative product development. The management team has improved the company’s commercial organization and executed growth initiatives to build its presence in e

AmTrust Financial Services and Blackstone Credit & Insurance Close Strategic Transaction and Launch Newly Formed Multinational MGACompany Named ANV Group Holdings Ltd.5.12.2025 13:00:00 CET | Press release

Strategic Transaction Unlocks Value for AmTrust and Positions ANV Group Holdings for Accelerated GrowthFormer AmTrust President Adam Karkowsky Leading ANV Group Holdings as Chairman and CEO AmTrust Financial Services, Inc. (“AmTrust” or the “Company”), a global specialty property casualty insurer, and Blackstone Credit & Insurance (“BXCI”), today announced the closing of a strategic transaction under which AmTrust and funds managed by BXCI have partnered to spin-off certain of AmTrust’s Managing General Agencies (“MGAs”) and fee-based businesses in the U.S., United Kingdom, and Continental Europe, into ANV Group Holdings Ltd. (“ANV”), a newly formed independent company, following receipt of regulatory approvals. AmTrust and ANV have entered into a ten-year capacity agreement through which AmTrust will remain the underwriter for the existing books of business offered through the MGAs. As previously announced on September 15, 2025, the agreement includes seven AmTrust subsidiaries: ANV S

Galderma Opens up New Chapter for Sculptra® with MDR Certification and New Expanded Indication for Body5.12.2025 07:00:00 CET | Press release

Sculptra®, the first proven regenerative biostimulator, has received European Union (EU) Medical Device Regulation (MDR) certification, expanding its current clinical application for the face to include gluteal area, posterior thighs, décolletage, and upper arms1 Studies investigating the efficacy of Sculptra on areas beyond the face show patients experienced progressive improvements in skin quality (including the improvement in cellulite appearance), firmness, lift, projection, and contour Sculptra’s versatility and new indication allow practitioners to shift patient treatment goals beyond rejuvenation toward enhancement, meeting evolving patient needs The certification validates Sculptra’s safety performance, efficacy, and quality, reinforcing Galderma’s commitment to innovation and meeting evolving patient needs Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the certification of Sculptra for body indications in the European Union (EU) following its

Northern Escape Heli-Skiing Takes the Title of “World’s Best Heli-Ski-Operator” for the 4th Year Running5.12.2025 02:40:00 CET | Press release

4x World’s Best Heli-Skiing Operation near Terrace, BC Northern Escape Heli-Skiing (NEH) has been named World’s Best Heli-Ski Operator 2025 by the World Ski Awards, marking its fourth straight victory following years 2022, 2023 and 2024. This recognition places NEH amongst an elite group of ski tourism operators consistently voted best in the world by industry leaders and enthusiasts alike. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251204074550/en/ A four-year run built on reliability NEH operates in British Columbia’s Skeena Mountains, where deep northern snow and vast terrain come together with small-group heli-skiing and heli snowboarding. When helicopters can’t safely fly, NEH has cat skiing readily available as a backup — an exceedingly rare offering in this industry. The operation spans over 833,571 wild acres of alpine bowls, glaciers and old-growth tree skiing. The NEH experience Guests choose from three lodge f

IDE034, a Bispecific ADC Licensed by Biocytogen to IDEAYA, Receives FDA IND Clearance5.12.2025 01:00:00 CET | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), announced that its partner IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision oncology company, has received the clearance of an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA) for the initiation of a Phase 1 clinical trial of IDE034, a potential first-in-class B7H3/PTK7 bispecific antibody-drug conjugate (ADC). IDEAYA expects to begin patient enrollment in Q1 2026, initially evaluating patients with solid tumors known to express B7H3 and PTK7, including lung, colorectal, head and neck, and ovarian/gynecological cancers. IDE034 is a bispecific B7H3/PTK7 TOP1 ADC, independently developed by Biocytogen and licensed to IDEAYA in July 2024. The IND clearance marks an important milestone for this licensed program, supporting subsequent clinical development of IDE034, while highlighting Biocytogen’s technical capabilities in bispecific ADC discovery and development. Dr. Yue

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye